<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289261</url>
  </required_header>
  <id_info>
    <org_study_id>MDICP01</org_study_id>
    <nct_id>NCT02289261</nct_id>
  </id_info>
  <brief_title>A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain</brief_title>
  <official_title>A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cukurova University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dexmedetomidine added to morphine is
      effective in the treatment of chronic cancer pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We conduct the study in Cukurova University Faculty of Medicine Research Hospital after
      obtaining ethics committee approval and patient's informed consent. Patients with cancer pain
      are allocated into two group to receive Patient Controlled Analgesia with morphine or
      morphine plus dexmedetomidine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption (mg)</measure>
    <time_frame>24 hours</time_frame>
    <description>cumulative morphine consumption for 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>24 hours</time_frame>
    <description>visual analog scale to assess pain degree</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine plus dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>morphine sulphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine plus dexmedetomidine</intervention_name>
    <description>Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval</description>
    <arm_group_label>Morphine plus dexmedetomidine</arm_group_label>
    <other_name>Morphine sulphate plus dexmedetomidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with chronic cancer pain

          -  between 20-80 years old age

        Exclusion Criteria:

          -  the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal)

          -  psychiatric or neurologic disease

          -  unable to communicate verbally

          -  nausea and vomiting

          -  patient's refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selcuk Gök, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cukurova University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cukurova University Faculty of Medicine Research Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Blaudszun G, Lysakowski C, Elia N, Tramèr MR. Effect of perioperative systemic α2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012 Jun;116(6):1312-22. doi: 10.1097/ALN.0b013e31825681cb. Review.</citation>
    <PMID>22546966</PMID>
  </reference>
  <results_reference>
    <citation>Lin TF, Yeh YC, Lin FS, Wang YP, Lin CJ, Sun WZ, Fan SZ. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth. 2009 Jan;102(1):117-22. doi: 10.1093/bja/aen320. Epub 2008 Nov 5.</citation>
    <PMID>18987053</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cukurova University</investigator_affiliation>
    <investigator_full_name>Ersel GULEC</investigator_full_name>
    <investigator_title>Ersel Gulec</investigator_title>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Morphine</keyword>
  <keyword>Dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

